Five retailers have sued Pfizer and Ranbaxy, alleging the drugmakers conspired to delay market entry of generic Lipitor in the U.S. Their ploy: “sham” compacts that forced the retailers to pay hundreds of millions of dollars more for atorvastatin than they otherwise would have, according to the lawsuit.
Drug Industry Daily